Capitainer has signed an agreement to provide its quantitative dried blood spot (qDBS) technology to AstraZeneca for broader clinical development programs intended create a more patient-centric method of monitoring trial participants’ responses to drugs.
Speaking to Medtech Insight, Capitainer’s CEO, Christopher Aulin, told the story of how his company realized the wider scope of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?